EDITORIAL
Is breast surgery time critical when neo-adjuvant therapy is not appropriate?
Marie E. Wood MD,
Corresponding Author
Marie E. Wood MD
Professor of Medicine
Hematology/Oncology Division, University of Vermont Larner College of Medicine, Burlington, VT, USA
Search for more papers by this authorMarie E. Wood MD,
Corresponding Author
Marie E. Wood MD
Professor of Medicine
Hematology/Oncology Division, University of Vermont Larner College of Medicine, Burlington, VT, USA
Search for more papers by this authorFirst published: 03 April 2021
No abstract is available for this article.
REFERENCES
- 1Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487-497.
- 2Curigliano G, Cardoso MJ, Poortmans P, et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast. 2020; 52: 8-16.
- 3Bartlett DL, Howe JR, Chang G, et al. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol. 2020; 27(6): 1717-1720.
- 4Dowsett M, Ellis MJ, Dixon JM, et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer. 2020; 6: 21.
- 5Alaidy Z, Mohamed A, Euhus D. Breast cancer progression when definitive surgery is delayed. Breast J. 2021; 27(4).
- 6Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12(11): 1527-1532.
- 7Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005; 23(22): 5108-5116.
- 8Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006; 106(10): 2095-2103.
- 9Ma CXSV, Leitch A, Santi S, et al. ALTERNATE: neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2-BC) in postmenopausal (PM) women: Alliance A011106. meeting abstract presented at. J Clin Oncol. 2020; 38(15_suppl): 504.
- 10Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016; 2(11): 1477-1486.
- 11Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study. Ann Surg Oncol. 2017; 24(2): 418-424.
- 12Weiss A, King TA, Mittendorf EA. The landmark series: neoadjuvant endocrine therapy for breast cancer. Ann Surg Oncol. 2020; 27(9): 3393-3401.
- 13Park KU, Gregory M, Bazan J, et al. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Res Treat. 2021: 1-10.
- 14Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US From 2010 to 2016. JAMA Netw Open. 2020; 3(8):e2013226.
